Showing results (1-10 of 87) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Urology|April 1, 2026
Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic reviewChiranjeev Sanyal, Ricardo Rendon
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 2, 2015
Renal cell carcinoma after neuroblastoma: A case study and review of the literatureBrendan Wallace, Michael Organ, Scott Bagnell, et al.
Urology|March 6, 2012
Clinical and pathologic factors of prognostic significance in penile squamous cell carcinoma in a North American populationGillian Bethune, Jeffrey Campbell, Adam Rocker, et al.
Healthcare Management Forum|April 23, 2025
The far-reaching impact of robotic-assisted surgery on healthcare systemsConnie Wong, Martin Beaumont, Tara Klassen, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 23, 2009
The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?Larry Goldenberg, Alan So, Neil Fleshner, et al.
The Canadian Journal of Urology|July 5, 2006
Does prolonging the time to renal cancer surgery affect long-term cancer control: a systematic review of the literatureMichael Jewett, Ricardo Rendon, George Dranitsaris, et al.
The Prostate|July 24, 2015
Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancerLynn N Thomas, Jennifer Merrimen, David G Bell, et al.
Urology|January 3, 2016
Evolving Strategies in the Treatment of Tuberous Sclerosis Complex-associated Angiomyolipomas (TSC-AML)Anil Kapoor, Louis Girard, Jean-Baptiste Lattouf, et al.
The Prostate|March 12, 2014
Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targetingLynn N Thomas, Jennifer Merrimen, David G Bell, et al.
American Journal of Clinical Oncology|August 8, 2012
Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trialMichael Organ, Lori Wood, Derek Wilke, et al.
Pageof 9